# SELLAS Life Sciences Shares Surge More Than 281% After Trial Results

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/59468
Published: 2026-11-17T14:15:49.000Z
Updated: 2026-11-17T14:15:49.000Z
Section: Investing

> The Phase 3 REGAL trial showed improved overall survival among patients with acute myeloid leukemia.

SELLAS Life Sciences shares surged more than 281% after the company announced positive results from its Phase 3 REGAL leukemia trial, which involved patients with acute myeloid leukemia.

SELLAS shares, which trade on Nasdaq as SLS, climbed above $28.

Trading volume exceeded 200 million shares.

The REGAL trial showed an improvement in overall survival among patients with acute myeloid leukemia.

The survival improvement was statistically significant.


